Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything

Merck agreed to buy Cidara Therapeutics for $9.2 billion in cash, sending Cidara shares up more than 100% and signaling a deliberate move to shore up growth ahead of Keytruda’s 2028 patent expiry. The prize is CD388, a Phase‑3, long‑acting, strain‑agnostic influenza antiviral with FDA Breakthrough and Fast Track designations that Merck pegs as a potential >$5 billion annual opportunity, and the deal follows recent bolt‑ons such as Verona Pharma as part of a broader external‑innovation strategy. With trailing twelve‑month net income north of $17 billion, a D/E around 0.7, a forward P/E near 10.4 and a dividend yield of roughly 3.4% (payout ~43%), Merck can absorb the price without stressing the balance sheet, and the acquisition materially diversifies revenue risk and supports the bullish case for the stock amid analyst upside expectations.

Analysis

Merck has agreed to acquire Cidara Therapeutics for $9.2 billion in cash, a transaction that pushed Cidara shares up more than 100% while Merck’s stock rose roughly 4% on the announcement; the deal is presented as a deliberate strategic response to Keytruda’s 2028 patent expiration and follows last month’s Verona Pharma acquisition. The target asset, CD388, is in Phase 3 and carries Breakthrough Therapy and Fast Track designations, described in the article as a long‑acting, strain‑agnostic influenza antiviral intended to provide season‑long protection from a single dose. Merck projects CD388 could exceed $5 billion in annual sales, and the article emphasizes that the Phase‑3 status materially reduces early clinical risk relative to preclinical assets. Merck’s ability to fund the deal is supported by trailing‑twelve‑month net income north of $17 billion, a D/E of ~0.69, a forward P/E near 10.4, and a dividend yield around 3.4% with a 42.8% payout ratio, implying the acquisition is financially manageable but still contingent on successful Phase‑3 outcomes, regulatory approval and commercial execution.

Key Decisions for Investors

• Consider maintaining or modestly adding to Merck (MRK) exposure given the acquisition adds a clear diversification pathway and the shares trade at a reasonable forward P/E, but size new exposure relative to portfolio risk tolerance
• Avoid purchasing Cidara (CDTX) equities at elevated post‑deal levels since the principal value transfer to shareholders has largely occurred and upside is now tied to deal completion terms
• Monitor near‑term catalysts closely: CD388 Phase‑3 readouts, FDA filing timelines tied to Breakthrough/Fast Track status, integration milestones and any analyst estimate revisions that would change the upside thesis
• Implement position protection (e.g., reducing concentrations or using hedges) around material clinical and regulatory binary events that will determine whether the projected >$5bn commercial case is realized